Navigation Links
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
Date:2/18/2009

ABBOTT PARK, Ill., and WATERTOWN, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration with a first-in-human study evaluating ABT-450, an oral protease inhibitor for the treatment of chronic HCV. The objectives of the trial include assessment of safety, tolerability and pharmacokinetics. ABT-450 was discovered as part of a worldwide alliance between Abbott and Enanta to discover, develop and commercialize protease inhibitors for the treatment of HCV.

"Hepatitis C is a serious global health concern, with 170 million people currently infected by six different HCV genotypes," said John M. Leonard, M.D., senior vice president, Global Pharmaceutical Research and Development, Abbott. "As a global leader in the development of antiviral therapies and diagnostics, Abbott is bringing its decades of antiviral experience, particularly with protease inhibitors, to this collaboration and to the fight against HCV."

"ABT-450 demonstrated favorable potency in vitro across various HCV genotypes and highly resistant strains," said Jay R. Luly, Ph.D., president and CEO of Enanta Pharmaceuticals. "We look forward to working with Abbott to advance ABT-450, and to our building a pipeline of HCV protease inhibitors that addresses this widespread disease."

Phase 1 Study Design

The Phase 1, double-blind, placebo-controlled study for ABT-450 announced today is a single, ascending oral dose trial in healthy volunteers.

About the Hepatitis C Virus

Hepatitis C is a liver disease affecting more than 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a per
'/>"/>

SOURCE Abbott; Enanta Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
2. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
3. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
4. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
5. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
6. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
7. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
8. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
9. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today reported financial results for the second ... "The second quarter of 2014 ... Doug Murphy-Chutorian , M.D., chief executive officer of ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... , May 20 As the medical device industry gathers ... of Sales Content Management software, offers medical device companies a solution to ... , , ... Sciences at Prolifiq, will lead the workshop "Sales-Friendly Compliant Content Communication: How ...
... NEW YORK , May 19 ... stage, specialty pharmaceutical and medical device company focused on ... Oncology (ASCO) has accepted an oral presentation of Delcath,s ... (PHP-mel) to the best alternative care for patients with hepatic ...
Cached Medicine Technology:Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 2Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 3Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago 2Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago 3
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 ... China Gel Permeation Chromatography Industryā€¯ is a ... Global and China Gel Permeation Chromatography market. ... information, including Gel Permeation Chromatography definition, classification, ... as industry overview. This research covers the ...
(Date:7/25/2014)... Los Angeles, CA (PRWEB) July 25, 2014 ... to talk about, and eager to reverse the symptoms associated ... health in the media at large, a new case ... the real benefits of testosterone therapy using bioidentical ... Jason, a 38-year-old father from Seattle who found himself beginning ...
(Date:7/25/2014)... 2014 American motor vehicle owners who ... can pay higher premiums for vehicle insurance on average. ... network to provide SR22 insurance for high risk motorists ... different coverage network of local agencies providing direct price ... platform now publicly available for any car owner to ...
(Date:7/25/2014)... As reported by the Statesman Journal in ... (7/20), police in Salem, MA as well as several ... recent heroin epidemic that has taken many lives during the ... overdose case in which police were able to make two ... By pretending to be the victim and claiming to want ...
Breaking Medicine News(10 mins):Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Multiple States Crack Down on Heroin Epidemic 2
... Calif., Dec. 8 Anesiva, Inc. (Nasdaq: ANSV ) ... with Arcion Therapeutics, Inc. ("Arcion") during its December 3, 2009 ... also approved a one-for-forty reverse stock split, which will be ... Closure of the merger remains contingent upon Anesiva achieving multiple ...
... PROVERI, Inc. is pleased to announce that it ... Venture Summit Top Innovator award by youngStartup Ventures. The list ... in innovation for the Technology, Life Sciences and Clean-tech sectors. , ... Executive Officer of PROVERI, Inc., will present the company at the ...
... , LONDON, Dec. 8 Over the past ... regarding the investment in healthcare information technology. Today, hospitals are ... in the Healthcare IT industry are in the process of ... an innovative product to market. At the same time, the ...
... , ANN ARBOR, Mich., Dec. ... revolutionary bench-top flow cytometer systems, today announced the 2009 recipients ... a free Accuri C6 Flow Cytometer® System each year to ... in Europe, who propose innovative uses of flow cytometry. ...
... ... 6.4 has just arrived. It offers new features for effectively working with Microsoft Office ... ... fanfare with interface updates and a powerful 64-bit capability. To date, InfoZoom has ...
... , LONDON, Dec. 8 Healthcare in ... of resources as the region,s working population is far lower in ... of new schemes in healthcare that would enable Europe to deal ... Information and Communication Technology (ICT) in healthcare is evident from the ...
Cached Medicine News:Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 3Health News:PROVERI, Inc. Named a Top Innovator Winner 2Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: